In celebration of Medscape's 25th birthday, we are highlighting key breakthroughs that have defined the last quarter century of medicine, as chosen by experts in their respective fields.
Over the past 25 years, cirrhosis and its related complications have undergone a fascinating evolution in the United States. Historically, cirrhosis was driven by viral hepatitis, yet despite curative therapy for hepatitis C and improvements in hepatitis B management, deaths from cirrhosis are expected to triple by 2030. This projection is driven by increasing rates of alcoholic liver disease and nonalcoholic fatty liver disease.
Hepatocellular carcinoma (HCC) is a known consequence of cirrhosis. As the etiologies causing cirrhosis change, liver cancer risk and rates are also evolving. Mortality data from 2000 to 2015 confirm an increase in liver cancer death rates, though hepatitis C virus (HCV) infection now accounts for less than one quarter of these cases.
Comorbid disorders other than cirrhosis add to HCC risk. This was best demonstrated when following individuals with cirrhosis secondary to HCV who had achieved a cure. Male sex, black race, alcohol use, type 2 diabetes, obesity, iron overload, hepatitis B co-infection, and advancing age were associated with the risk of developing liver cancer despite viral eradication
Liquid Biopsy in HCC Offers Valuable Tool for Detection, Disease Monitoring
Immunotherapy Treatment Shows Promise for Resectable Liver Cancer
Hepatocellular Carcinoma (HCC)
Hepatocellular Carcinoma Clinical Practice Guidelines (AGA, 2022)
COMMENTARY
Liver Cancer Rates Are Rising; So Is Optimism Around Its Treatment
Nancy S. Reau, MD
DisclosuresNovember 20, 2020
In celebration of Medscape's 25th birthday, we are highlighting key breakthroughs that have defined the last quarter century of medicine, as chosen by experts in their respective fields.
Over the past 25 years, cirrhosis and its related complications have undergone a fascinating evolution in the United States. Historically, cirrhosis was driven by viral hepatitis, yet despite curative therapy for hepatitis C and improvements in hepatitis B management, deaths from cirrhosis are expected to triple by 2030. This projection is driven by increasing rates of alcoholic liver disease and nonalcoholic fatty liver disease.
Hepatocellular carcinoma (HCC) is a known consequence of cirrhosis. As the etiologies causing cirrhosis change, liver cancer risk and rates are also evolving. Mortality data from 2000 to 2015 confirm an increase in liver cancer death rates, though hepatitis C virus (HCV) infection now accounts for less than one quarter of these cases.
Comorbid disorders other than cirrhosis add to HCC risk. This was best demonstrated when following individuals with cirrhosis secondary to HCV who had achieved a cure. Male sex, black race, alcohol use, type 2 diabetes, obesity, iron overload, hepatitis B co-infection, and advancing age were associated with the risk of developing liver cancer despite viral eradication
Medscape Gastroenterology © 2020 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Liver Cancer Rates Are Rising; So Is Optimism Around Its Treatment - Medscape - Nov 20, 2020.
Tables
Authors and Disclosures
Authors and Disclosures
Author
Nancy S. Reau, MD
Professor, Department of Internal Medicine, Rush University; Section Chief, Hepatology; Associate Director of Organ Transplant, Rush University Medical Center, Chicago, Illinois
Disclosure: Nancy S. Reau, MD, has disclosed the following financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: AbbVie Inc.; Gilead Sciences, Inc.; Bristol-Myers Squibb Company; Merck & Co., Inc.; Intercept Pharmaceuticals, Inc.
Received income in an amount equal to or greater than $250 from: American Board of Internal Medicine